DexTech Medical (DEX) Q3 2026 earnings summary

Executive summary

• No net sales were recorded for the third quarter or nine-month period compared to the same periods last year.

• Operating losses increased both in the quarter (SEK -1.7 million vs. -1.3 million) and nine months (SEK -4.8 million vs. -3.7 million) year-over-year.

• The lead drug candidate, OsteoDex, showed promising results in a Phase I/IIa study for relapsed/treatment-resistant multiple myeloma, with over 80% of patients achieving stable disease and no serious treatment-related side effects.

• The study is expected to conclude with a formal report in Q3 2026, slightly later than previously announced.

• Current liquidity is projected to finance operations through at least the end of 2028.

Financial highlights

• Net sales were SEK 0.0 million for both the quarter and nine-month period, unchanged year-over-year.

• Operating profit was SEK -1.7 million for Q3 (vs. -1.3 million) and SEK -4.8 million for nine months (vs. -3.7 million).

• Earnings per share were SEK -0.09 for Q3 (vs. -0.07) and SEK -0.25 for nine months (vs. -0.18).

• Cash and cash equivalents at period end were SEK 10.1 million (vs. 14.7 million).

• Equity at period end was SEK 20.1 million (vs. 24.8 million), with an equity/assets ratio of 97% (vs. 99%).

Outlook and guidance

• Working capital is sufficient to finance operations until at least the end of 2028.

• The company aims for future license revenues to support ongoing operations.

• The Phase I/IIa study report for OsteoDex in multiple myeloma is expected in Q3 2026.

• Strategic partnerships are being pursued for further clinical development.